home / stock / rtrx / rtrx quote
Last: | $24.24 |
---|---|
Change Percent: | -0.49% |
Open: | $24.57 |
Close: | $24.24 |
High: | $24.74 |
Low: | $24.04 |
Volume: | 378,991 |
Last Trade Date Time: | 11/18/2020 04:56:39 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$24.24 | $24.57 | $24.24 | $24.74 | $24.04 | 378,991 | 11-18-2020 |
$24.36 | $23.98 | $24.36 | $24.57 | $23.71 | 453,146 | 11-17-2020 |
$24.11 | $23.94 | $24.11 | $24.59 | $23.68 | 409,952 | 11-16-2020 |
$23.68 | $23.81 | $23.68 | $24.44 | $23.33 | 289,237 | 11-13-2020 |
$23.53 | $23.8 | $23.53 | $24.54 | $23.41 | 193,493 | 11-12-2020 |
$24 | $23.86 | $24 | $24.96 | $23.56 | 294,407 | 11-11-2020 |
$23.66 | $22.79 | $23.66 | $23.83 | $22.63 | 537,704 | 11-10-2020 |
$22.66 | $22.24 | $22.66 | $23.325 | $21.36 | 474,296 | 11-09-2020 |
$21.57 | $22.28 | $21.57 | $23.69 | $21.39 | 609,555 | 11-06-2020 |
$20.89 | $21.26 | $20.89 | $21.45 | $20.65 | 226,871 | 11-05-2020 |
$21.24 | $20.74 | $21.24 | $22.49 | $20.4644 | 469,166 | 11-04-2020 |
$20.74 | $20.43 | $20.74 | $20.91 | $19.94 | 374,132 | 11-03-2020 |
$20.15 | $20.48 | $20.15 | $20.58 | $19.52 | 247,693 | 11-02-2020 |
$20.24 | $20.76 | $20.24 | $20.79 | $19.83 | 229,337 | 10-30-2020 |
$20.78 | $20.96 | $20.78 | $21.02 | $20.42 | 138,488 | 10-29-2020 |
$21.02 | $21.19 | $21.02 | $21.36 | $20.8 | 270,892 | 10-28-2020 |
$21.51 | $20.99 | $21.51 | $21.58 | $20.61 | 207,508 | 10-27-2020 |
$21 | $20.74 | $21 | $21.3 | $20.55 | 247,424 | 10-26-2020 |
$20.95 | $21.48 | $20.95 | $21.48 | $19.53 | 405,474 | 10-23-2020 |
$21.08 | $20.7 | $21.08 | $21.46 | $20.555 | 246,486 | 10-22-2020 |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...